12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Marqibo vincristine regulatory update

FDA granted accelerated approval to an NDA from Talon for Marqibo vincristine to treat Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in patients with >=2 relapses or in patients whose cancer has progressed following >=2 leukemia therapies. Talon plans to launch the nanoparticle liposomal formulation of vincristine in 1Q13. The company said it will disclose the price...

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >